Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway
Overview
Authors
Affiliations
Background Oral anticoagulation reduces stroke and disability in atrial fibrillation (AF) but is underused. We evaluated the effects of a novel patient-clinician shared decision-making (SDM) tool in reducing oral anticoagulation patient's decisional conflict as compared with usual care. Methods and Results We designed and evaluated a new digital decision aid in a multicenter, randomized, comparative effectiveness trial, ENHANCE-AF (Engaging Patients to Help Achieve Increased Patient Choice and Engagement for AF Stroke Prevention). The digital AF shared decision-making toolkit was developed using patient-centered design with clear health communication principles (eg, meaningful images, limited text). Available in English and Spanish, the toolkit included the following: (1) a brief animated video; (2) interactive questions with answers; (3) a quiz to check on understanding; (4) a worksheet to be used by the patient during the encounter; and (5) an online guide for clinicians. The study population included English or Spanish speakers with nonvalvular AF and a CHADS-VASc stroke score ≥1 for men or ≥2 for women. Participants were randomized in a 1:1 ratio to either usual care or the shared decision-making toolkit. The primary end point was the validated 16-item Decision Conflict Scale at 1 month. Secondary outcomes included Decision Conflict Scale at 6 months and the 10-item Decision Regret Scale at 1 and 6 months as well as a weighted average of Mann-Whitney -statistics for both the Decision Conflict Scale and the Decision Regret Scale. A total of 1001 participants were enrolled and followed at 5 different sites in the United States between December 18, 2019, and August 17, 2022. The mean patient age was 69±10 years (40% women, 16.9% Black, 4.5% Hispanic, 3.6% Asian), and 50% of participants had CHADS-VASc scores ≥3 (men) or ≥4 (women). The primary end point at 1 month showed a clinically meaningful reduction in decisional conflict: a 7-point difference in median scores between the 2 arms (16.4 versus 9.4; Mann-Whitney -statistics=0.550; =0.007). For the secondary end point of 1-month Decision Regret Scale, the difference in median scores between arms was 5 points in the direction of less decisional regret (=0.078). The treatment effects lessened over time: at 6 months the difference in medians was 4.7 points for Decision Conflict Scale (=0.060) and 0 points for Decision Regret Scale (=0.35). Conclusions Implementation of a novel shared decision-making toolkit (afibguide.com; afibguide.com/clinician) achieved significantly lower decisional conflict compared with usual care in patients with AF. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04096781.
Patient-Selection of a Clinical Trial Primary Outcome: The ENHANCE-AF Outcomes Survey.
Stafford R, Rice E, Shah R, Hills M, Nunes J, DeSutter K PLoS One. 2025; 20(3):e0318858.
PMID: 40053524 PMC: 11888126. DOI: 10.1371/journal.pone.0318858.
Ozanne E, Barnes G, Brito J, Cameron K, Cavanaugh K, Greene T BMJ. 2025; 388:e079976.
PMID: 39788611 PMC: 11713231. DOI: 10.1136/bmj-2024-079976.
Brar S, Townsend J, Phulka J, Halperin L, Liew J, Parker J Eur J Hum Genet. 2024; .
PMID: 39645542 DOI: 10.1038/s41431-024-01762-0.
McLoughlin D, Moreno Echevarria F, Badawy S JMIR Cancer. 2024; 10:e56935.
PMID: 39187430 PMC: 11425020. DOI: 10.2196/56935.
Zeng A, Tang Q, OHagan E, McCaffery K, Ijaz K, Quiroz J BMJ Evid Based Med. 2024; 30(1):10-21.
PMID: 38950915 PMC: 11874357. DOI: 10.1136/bmjebm-2023-112820.